News

First collaborative deal for Conformetrix

Manchester and London, UK, April 16 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Manchester, UK, March 7 2012 – The Board of Conformetrix Ltd, a leader in optimising drug discovery and design, has appointed Dr Sam Williams as Chief Executive Officer, it is announced today.